DNAprint Genomics (DNAG)

[sam1933]

Excellent! Excellent Phase III-results with BF-200 ALA

better drugs for segmented markets

PT-500 & PT-200
Our PT-500 series comprise three related compounds (PT-501, PT-502 and PT-503) being developed for attention deficit and hyperactivity disorder, drug addiction and depression, respectively. Early preclinical animal models show that the compounds are selective, with a high degree of activity when compared side by side with competing compounds, such as serotonin-reuptake inhibitors. Our PT-200 series of compounds are Phase III candidates licensed from our German partner, Biofrontera, for ocular and nasal allergies, and are designed to provide a revenue and corporate-development bridge to the company …
http://www.google.com/search?hl=en&rls=com.microsoft%3Aen-us%3AIE-SearchBox&rlz=1I7SNYC_en&q=Phase+III+Biofrontera+ocular+allergies+a+revenue&btnG=Search